Related Experiment Video
Updated: Dec 26, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Adefovir dipivoxil induces DNA replication stress and augments ATR inhibitor-related cytotoxicity
Agata Patel1, Elena Seraia2, Daniel Ebner2
1The Department of Oncology, Oxford Institute for Radiation Oncology, University of Oxford, Oxford, United Kingdom.
Abstract:
Replication stress is a common feature of cancer cells. Ataxia telangiectasia-mutated (ATM) and Rad3-related (ATR) signalling, a DNA damage repair (DDR) pathway, is activated by regions of single-stranded DNA (ssDNA) that can arise during replication stress. ATR delays cell cycle progression and prevents DNA replication fork collapse, which prohibits cell death and promotes proliferation. Several ATR inhibitors have been developed in order to restrain this protective mechanism in tumours. It is known, however, that despite other effective anticancer chemotherapy treatments targeting DDR pathways, resistance occurs. This begets the need to identify combination treatments to overcome resistance and prevent tumour cell growth. We conducted a drug screen to identify potential synergistic combination treatments by screening an ATR inhibitor (VE822) together with compounds from a bioactive small molecule library. The screen identified adefovir dipivoxil, a reverse transcriptase inhibitor and nucleoside analogue, as a compound that has increased cytotoxicity in the presence of ATR, but not ATM or DNA-dependant protein kinase (DNA-PK) inhibition. Here we demonstrate that adefovir dipivoxil induces DNA replication stress, activates ATR signalling and stalls cells in S phase. This simultaneous induction of replication stress and inhibition of ATR signalling lead to a marked increase in pan-nuclear γH2AX-positive cells, ssDNA accumulation and cell death, indicative of replication catastrophe.
Insights
Combining ATR inhibitors with adefovir dipivoxil overcomes cancer cell resistance. This novel strategy induces replication stress and inhibits ATR signaling, leading to cancer cell death.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Replication stress is prevalent in cancer cells, activating DNA damage repair (DDR) pathways like ATM and Rad3-related (ATR) signaling.
- ATR signaling protects cancer cells by delaying cell cycle progression and preventing replication fork collapse, promoting proliferation.
- Resistance to existing DDR-targeting therapies necessitates the development of novel combination treatments.
Purpose of the Study:
- To identify synergistic combination treatments to overcome resistance in cancer therapies.
- To screen for compounds that enhance the cytotoxicity of ATR inhibitors.
Main Methods:
- A drug screen was performed, combining an ATR inhibitor (VE822) with compounds from a bioactive small molecule library.
- Cytotoxicity was assessed in the presence of ATR, ATM, or DNA-PK inhibition.
- Mechanisms of action, including replication stress induction and ATR signaling activation, were investigated.
Main Results:
- Adefovir dipivoxil demonstrated increased cytotoxicity when combined with ATR inhibition, but not ATM or DNA-PK inhibition.
- Adefovir dipivoxil was found to induce DNA replication stress and activate ATR signaling, stalling cells in S phase.
- The combination of adefovir dipivoxil and ATR inhibition resulted in increased γH2AX foci, ssDNA accumulation, and cell death, indicating replication catastrophe.
Conclusions:
- Adefovir dipivoxil is a potent sensitizer to ATR inhibition in cancer cells.
- Simultaneous induction of replication stress and ATR inhibition represents a promising strategy to induce replication catastrophe and overcome therapeutic resistance.
- This combination therapy holds potential for treating tumors that rely on ATR signaling for survival.
Related Concept Videos
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Subviral Agents
Therapeutic Drug Monitoring: Affecting Factors
The DNA Replication Fork

